nach oben

Erschienen in:

10.05.2019 | Gynecologic Oncology

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer

verfasst von: Umran Kucukgoz Gulec, Emine Kilic Bagir, Semra Paydas, Ahmet Baris Guzel, Derya Gumurdulu, Mehmet Ali Vardar

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate prognostic importance of programmed death-1 (PD-1) and/ or programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.

Study design

Formalin-fixed, paraffin-embedded tissue samples from 53 cases with type 2 endometrial cancer were analyzed. One-third of our cases had serous adenocarcinoma (32%), 11 had clear cell (21%) and 25 had mixed-type adenocarcinoma (47%). PD-1 and PD-L1 expressions in tumor tissue and microenvironment were detected by immunohistochemistry. Clinical and pathological characteristics including age, stage, initial symptom, surgical procedure, myometrial invasion, lymphovascular space invasion (LVSI), lymph node invasion, adjuvant therapy, and survival were reviewed. The Kaplan–Meier and Cox proportional hazards models were used to evaluate the prognostic factors.

Results

PD-1 expression in tumor tissue and microenvironment was detected in 22 (42%) and 28 (53%) cases, respectively. PD-L1 expression was detected in tumor and microenvironment in 8 (15%) and in 15 cases (28%), respectively. Expression of PD-1 and PD-L1 expressions in tumor area was associated with shorter survival (p = 0.006 and 0.001, respectively) but PD-1 and PD-L1 expressions in microenvironment were not found to be related with survival. PD-1 (p = 0.006) and PD-L1 expressions (p = 0.001) in addition to LVSI (p = 0.005), myometrial invasion (p = 0.015), lymph node involvement (p = 0.019), and suboptimal cytoreduction (p = 0.042), were found to be associated with poor prognostic indicators. PD-1 and PD-L1 expressions in tumor and lymph node involvement were determined as independent prognostic factors.

Conclusion

PD-1 and PD-L1 expressions in type 2 endometrial cancers were found to be poor prognostic indicators.

Suarez AA, Felix AS, Cohn DE (2017) Bokhman Redux: Endometrial cancer "types" in the 21st century. Gynecol Oncol 144(2):243–249CrossRefPubMed

Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A et al (2008) Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198(2):218.e1–6CrossRef

Murali R, Soslow RA, Weigelt B (2014) Classification of endometrial carcinoma: more than two types. Lancet Oncol 15(7):e268–e278CrossRefPubMed

Piulats JM, Guerra E, Gil-Martín M, Roman-Canal B, Gatius S, Sanz-Pamplona R et al (2017) Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 145(1):200–207CrossRefPubMed

Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I (2016) PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 21(3):462–473CrossRefPubMedPubMedCentral

Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L et al (2016) Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated endometrial cancers: New candidates for checkpoint blockade immunotherapy? Cancer Treat Rev 48:61–68CrossRefPubMed

Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J et al (2016) Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget 7(21):30772–30780PubMedPubMedCentral

Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(Pt 23):5591–5596CrossRefPubMed

Xiao X, Dong D, He W, Song L, Wang Q, Yue J et al (2018) Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer. Gynecol Oncol 149(1):146–154CrossRefPubMed

10.

Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F (2014) Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 63(6):545–557CrossRefPubMedPubMedCentral

11.

Yamashita H, Nakayama K, Ishikawa M, Nakamura K, Ishibashi T, Sanuki K, et al. (2017) Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget 31;9(5):5652–5664.

12.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372(26):2509–2520CrossRefPubMedPubMedCentral

13.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413CrossRefPubMedPubMedCentral

14.

Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM (2017) PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Am J Surg Pathol 41(3):326–333CrossRefPubMed

15.

Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H et al (2017) Characterization of immune regulatory molecules B7–H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol 145(3):446–452CrossRefPubMed

16.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L et al (2016) Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology 6(2):e1264565CrossRefPubMedPubMedCentral

17.

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S et al (2015) Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers with Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol 1(9):1319–1323CrossRefPubMed

18.

Paydas S, Bagir EK, Deveci MA, Gonlusen G (2016) Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol 33(8):93CrossRefPubMed

19.

D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L et al (2015) PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112(1):95–102CrossRefPubMed

20.

Weinberg LE, Kunos CA, Zanotti KM (2013) Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk early-stage endometrioid endometrial cancer. Int J Gynecol Cancer 23(8):1438–1445CrossRefPubMed

21.

Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW et al (2015) Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer–A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 51(13):1742–1750CrossRefPubMed

22.

Slomovit BM, Burk TW, Eife PJ, Ramondetta LM, Silva EG, Jhingran A et al (2003) Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91(3):463–469CrossRef

23.

Mittica G, Ghisoni E, Giannone G, Aglietta M, Genta S, Valabrega G (2017) Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 8(52):90532–90544CrossRefPubMedPubMedCentral

Titel: Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
verfasst von: Umran Kucukgoz Gulec
Emine Kilic Bagir
Semra Paydas
Ahmet Baris Guzel
Derya Gumurdulu
Mehmet Ali Vardar
Publikationsdatum: 10.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05180-2

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer

Abstract

Purpose

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Purpose

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Modulation effect of vaginal mucosal microflora and susceptibility to Neisseria gonorrhoeae infections: a systematic review and meta-analysis

Adverse pregnancy outcomes and multiple nuchal cord loops

Correction to: Once episiotomy, always episiotomy?

Low–moderate prenatal alcohol exposure and offspring attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis

Review on current treatment options for lesions of uncertain malignant potential (B3 lesions) of the breast: do B3 papillary lesions need to be removed in any case by open surgery?

Quality of life in breast cancer patients and surgical results of immediate tissue expander/implant-based breast reconstruction after mastectomy

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie